At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CDMO Avid Bioservices, Inc.
Halted 12-12 18:05:17 EST
12.49
+0.00
0.00%
High12.49Low12.49Vol0.00
Open12.49D1 Closing12.49Amplitude0.00%
Mkt Cap798.90MTradable Cap632.28MTotal Shares63.96M
T/O38.32MT/O Rate0.00%Tradable Shares50.62M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

First Case of Staggered Payment in M&A Consideration Approved by SSE's Restructuring Committee
Deep News  ·  12-10 07:12
First Case of Staggered Payment in M&A Consideration Approved by SSE's Restructuring Committee
Lepu Biopharma (SEHK:2157): Valuation Check After New GLP-1 CDMO Framework Deal With Lepu Medical
Simply Wall St.  ·  12-05
Lepu Biopharma (SEHK:2157): Valuation Check After New GLP-1 CDMO Framework Deal With Lepu Medical
SCTbio and Fortrea Forge Strategic Collaboration to Accelerate Cell and Gene Therapy Development and Delivery
GlobeNewswire  ·  12-04
SCTbio and Fortrea Forge Strategic Collaboration to Accelerate Cell and Gene Therapy Development and Delivery
Press Release: Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances
Dow Jones  ·  12-02
Press Release: Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances
BioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500 Million Equity Facility From ARC Group International to Support Expansion of Precision Diagnostics, CDMO Operations, and Therapeutic Commercialization
GlobeNewswire  ·  12-02
BioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500 Million Equity Facility From ARC Group International to Support Expansion of Precision Diagnostics, CDMO Operations, and Therapeutic Commercialization
Amaran Biotech's Vaccine Adjuvant AB-801 Receives FDA Drug Master File (DMF) Filing Acknowledgement
prnewswire  ·  12-02
Amaran Biotech's Vaccine Adjuvant AB-801 Receives FDA Drug Master File (DMF) Filing Acknowledgement
LEPU BIO-B (02157) Enters into CDMO Service Framework Agreement with Lepu Medical
Stock News  ·  11-28
LEPU BIO-B (02157) Enters into CDMO Service Framework Agreement with Lepu Medical
China Securities Co., Ltd.: CXO Sector Adjustment Nears Completion, Focus on CDMO Firms with Strong Overseas Expansion and Leading Clinical CROs
Stock News  ·  11-24
China Securities Co., Ltd.: CXO Sector Adjustment Nears Completion, Focus on CDMO Firms with Strong Overseas Expansion and Leading Clinical CROs
Samsung Biologics' Spin-Off Likely to Accelerate CDMO Growth -- Market Talk
Dow Jones  ·  11-20
Samsung Biologics' Spin-Off Likely to Accelerate CDMO Growth -- Market Talk
Integer to Participate at Upcoming Investor Conferences
GlobeNewswire  ·  11-18
Integer to Participate at Upcoming Investor Conferences
A Closer Look at Thermo Fisher Scientific's (TMO) Valuation After Recent Share Price Strength
Simply Wall St.  ·  11-17
A Closer Look at Thermo Fisher Scientific's (TMO) Valuation After Recent Share Price Strength
Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates
GlobeNewswire  ·  11-12
Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates
Lifecore Biomedical to Participate in Upcoming Investor Conferences
GlobeNewswire  ·  11-12
Lifecore Biomedical to Participate in Upcoming Investor Conferences
Pluri Partners with Miss Universe Skincare Introducing Exosome-Enhanced Regenerative Skincare
GlobeNewswire  ·  11-11
Pluri Partners with Miss Universe Skincare Introducing Exosome-Enhanced Regenerative Skincare
Apeloa Pharmaceutical, Anticon Biotech Strike CDMO Tie-Up
MT Newswires Live  ·  11-07
Apeloa Pharmaceutical, Anticon Biotech Strike CDMO Tie-Up
Biomerica Expands Contract Development and Manufacturing Services to Meet Growing Market Demand
GlobeNewswire  ·  11-06
Biomerica Expands Contract Development and Manufacturing Services to Meet Growing Market Demand
UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial
GlobeNewswire  ·  11-06
UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial
Press Release: Piramal Pharma Limited Announces Results for Q2 and H1 FY26
Dow Jones  ·  11-06
Press Release: Piramal Pharma Limited Announces Results for Q2 and H1 FY26
Integer Holdings Corporation Board Authorizes $200 Million Share Repurchase Program
GlobeNewswire  ·  11-04
Integer Holdings Corporation Board Authorizes $200 Million Share Repurchase Program
LOTTE BIOLOGICS and SK pharmteco Sign Strategic Partnership to Strengthen Global ADC CDMO Capabilities
prnewswire  ·  10-30
LOTTE BIOLOGICS and SK pharmteco Sign Strategic Partnership to Strengthen Global ADC CDMO Capabilities

Introduction

Company Name.
Avid Bioservices, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services of biologics for the biotechnology and biopharmaceutical industries. The company offers various services, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.
Issue price:
--